Tempus AI Target Slashed to $64, Following Wider Q1 Net Loss

H.C. Wainwright maintained its Buy rating on Tempus AI while lowering the 12-month price target from $95 to $64. This 32.6% reduction follows the company’s first-quarter financial results.

Tempus AI reported a net loss of $125.9 million, exceeding analyst expectations. Revenue grew 36.1% year-over-year to reach $348.1 million. The firm cited a cautious outlook on valuation and growth prospects for the adjustment.

Cathie Wood’s ARK Invest purchased over 300,000 shares of Tempus AI, a stake valued at more than $15 million.

Subsidiary Ambry Genetics received the Best Overall Health Informatics Solution award at the 2026 MedTech Breakthrough Awards for its CARE Program.